

Author's Accepted Manuscript

Substrates and potential therapeutics of ventricular arrhythmias in heart failure

Dongze Zhang, Huiyin Tu, Michael C. Wadman, Yu-Long Li



PII: S0014-2999(18)30357-1
DOI: <https://doi.org/10.1016/j.ejphar.2018.06.024>
Reference: EJP71854

To appear in: *European Journal of Pharmacology*

Received date: 9 March 2018
Revised date: 30 April 2018
Accepted date: 19 June 2018

Cite this article as: Dongze Zhang, Huiyin Tu, Michael C. Wadman and Yu-Long Li, Substrates and potential therapeutics of ventricular arrhythmias in heart failure, *European Journal of Pharmacology*, <https://doi.org/10.1016/j.ejphar.2018.06.024>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Substrates and potential therapeutics of ventricular arrhythmias in heart failure

Dongze Zhang, Huiyin Tu, Michael C. Wadman, Yu-Long Li*

Department of Emergency Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA

*Corresponding author: Yu-Long Li, MD, PhD. Department of Emergency Medicine, University of Nebraska Medical Center, 985850 Nebraska Medical Center, Omaha, NE 68198-5850, USA; Tel.: +1-402-559-3016; Fax: +1-402-559-9659. E-mail: yulongli@unmc.edu

Abstract

Heart failure (HF) is a clinical syndrome characterized by ventricular contractile dysfunction. About 50% of death in patients with HF are due to fatal ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation. Understanding ventricular arrhythmic substrates and discovering effective antiarrhythmic interventions are extremely important for improving the prognosis of patients with HF and reducing its mortality. In this review, we discussed ventricular arrhythmic substrates and current clinical therapeutics for ventricular arrhythmias in HF. Base on the fact that classic antiarrhythmic drugs have the limited efficacy, side effects, and proarrhythmic potentials, we also updated some therapeutic strategies for the development of potential new antiarrhythmic interventions for patients with HF.

Keywords: Antiarrhythmic drugs, Catheter ablation, Heart failure, Ventricular arrhythmia, Ventricular arrhythmic substrate

Download English Version:

<https://daneshyari.com/en/article/8529021>

Download Persian Version:

<https://daneshyari.com/article/8529021>

[Daneshyari.com](https://daneshyari.com)